NasdaqGM:MIRMBiotechs
Mirum’s VISTAS Success And What It Could Mean For MIRM Shareholders
Mirum Pharmaceuticals reported positive topline VISTAS Phase 2b results for volixibat in primary sclerosing cholangitis related cholestatic pruritus.
The trial showed a robust, clinically meaningful improvement in itch symptoms for PSC patients, who currently have no approved treatment options.
Following the data, Mirum has a pre NDA meeting scheduled and plans to file for regulatory approval for volixibat.
For investors tracking Mirum Pharmaceuticals, ticker NasdaqGM:MIRM, this update sits...